Myasthenia gravis market value set to treble by 2024: Report

14 July 2015

The global market for myasthenia gravis therapeutics is anticipated to more than treble in value from $146.4 million in 2014 to $550.4 million by 2024, driven primarily by the potential entry of Alexion Pharmaceuticals’ (Nasdaq: ALXN) Soliris (eculizumab) during the forecast period, new research indicates.

According to research and consulting firm GlobalData’s latest report, while only a small percentage of refractory myasthenia gravis patients would receive Soliris across the seven major markets (7MM) of the USA, France, Germany, Italy, Spain, UK, and Japan, the drug has the potential to have a notable impact on growth due to its premium pricing.

Melina Reisenberg, GlobalData’s analyst covering neurology, says Soliris is expected to launch in the USA in 2018, followed by its entry in the five European countries (5EU) and Japan in 2019 and 2020, respectively.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK